A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Modified glucagon-like peptide 1 (GLP-1) plays a crucial role in type 2 diabetes (T2D) treatment. The comparative hypoglycemic effect among fatty-acid-modified GLP-1 monomer G20, dimer 2G21, and tetramer 4G18 was evaluated in T2D mice. The polymers e…
Substance use disorders (SUDs) remain a major public health challenge, with existing pharmacotherapies offering limited long-term efficacy. Traditional treatments focus on dopaminergic systems but often overlook the complex interplay between metaboli…
Semaglutide, a glucagon-like peptide-1 receptor agonist widely used for managing type 2 diabetes mellitus and obesity. Reports of semaglutide-associated hepatotoxicity are exceedingly rare. We detail a case of a 44-year-old woman who developed liver…
Reports submitted to the FDA and EMA suggest that Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) may be associated with an elevated risk of suicidality. To ascertain this association across available pharmacovigilance and cohort studies, Pubme…
Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and weight management, are known for their metabolic benefits but may have unrecognized side effects. This study investigates the association between GLP-1 recep…
Loss of lean mass is a potential concern for semaglutide-induced weight loss. This study indicates that semaglutide has unexpected effects on skeletal muscle mass and strength in mice, demonstrating a need to more carefully assess these effects in hu…
Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising pharmacological intervention in obesity management. This systematic review aimed to evaluate the efficacy and safety of semaglutide in promoting weight loss in adults…
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with body weight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy i…
This study aimed to systematically review existing evidence on the preoperative use of GLP-1 receptor agonists (GLP-1 RA) before metabolic and bariatric surgery (MBS). Web of Science, Embase, PubMed, and Scopus were searched systematically with relev…
INTRODUCTION: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood. METHODS: Patients with IBD treated with GLP1-RA were retrospectively identified f…
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack of data evaluating the types of reactions associated wit…
BACKGROUND: To compare the effects of switching from dipeptidyl peptidase 4 (DPP-4) inhibitors to oral semaglutide on oxidative stress and glucose variability assessed by continuous glucose monitoring in patients with type 2 diabetes mellitus (T2DM).…
BACKGROUND: The treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood gl…
BACKGROUND: CKD is a significant public health issue, affecting approximately half a billion people globally. Key risk factors for CKD include obesity, hypertension, cardiovascular diseases and diabetes. Glucagon-like peptide-1 receptor agonists (GLP…
OBJECTIVE: Investigate the impact and mechanism of semaglutide (Sema) combined with high-intensity interval training (HIIT) on hepatic glucose/lipid metabolism in db/db mice using untargeted metabolomics. METHODS: Db/db mice were divided into model c…
Our study focused on a mouse model of obesity induced by a high-fat diet (HFD). We administered Semaglutide intraperitoneally (Ozempic ®-0.05 mg/Kg-translational dose) every seven days for six weeks. HFD-fed mice had higher blood glucose, lipid profi…
AIMS: Obesity and overweight pose significant global health challenges necessitating effective pharmacological interventions. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged for their weight-reducing effects in non-diabetic individ…
BACKGROUND: Sodium-glucose transporter 2 inhibitors (SGLT-2Is) and Semaglutide may increase the risk of sarcopenia and bone fragility in vulnerable populations, yet their effects on body composition in patients with type 2 diabetes mellitus (T2DM) an…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide (Wegovy®), are increasingly used for weight management in both adult and pediatric populations. Their mechanism of delayed gastric emptying raises concern for aspiration dur…